Haemonetics Corporation (HAE) Receives Average Rating of “Hold” from Analysts

Shares of Haemonetics Corporation (NYSE:HAE) have been assigned an average recommendation of “Hold” from the nine ratings firms that are presently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, four have issued a hold rating and three have issued a buy rating on the company. The average twelve-month price target among analysts that have covered the stock in the last year is $44.60.

Several equities analysts have commented on the company. Zacks Investment Research cut Haemonetics Corporation from a “buy” rating to a “hold” rating in a research note on Wednesday, August 16th. JMP Securities raised Haemonetics Corporation from a “market perform” rating to an “outperform” rating and set a $50.00 target price for the company in a research note on Thursday, July 13th. BidaskClub raised Haemonetics Corporation from a “strong sell” rating to a “sell” rating in a research note on Tuesday, August 8th. Jefferies Group LLC reaffirmed a “buy” rating and set a $48.00 target price on shares of Haemonetics Corporation in a research note on Thursday, July 27th. Finally, TheStreet raised Haemonetics Corporation from a “c” rating to a “b-” rating in a research note on Monday, August 7th.

COPYRIGHT VIOLATION WARNING: “Haemonetics Corporation (HAE) Receives Average Rating of “Hold” from Analysts” was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this piece can be read at https://www.dispatchtribunal.com/2017/10/28/haemonetics-corporation-hae-receives-average-rating-of-hold-from-analysts.html.

Haemonetics Corporation (NYSE:HAE) opened at 45.58 on Thursday. The firm has a market cap of $2.40 billion, a PE ratio of 591.95 and a beta of 0.87. Haemonetics Corporation has a 12 month low of $32.76 and a 12 month high of $46.85. The firm’s 50-day moving average is $43.95 and its 200-day moving average is $41.73.

Haemonetics Corporation (NYSE:HAE) last announced its quarterly earnings data on Monday, August 7th. The medical instruments supplier reported $0.33 earnings per share for the quarter, topping the consensus estimate of $0.31 by $0.02. Haemonetics Corporation had a return on equity of 11.07% and a net margin of 0.48%. The business had revenue of $211.00 million during the quarter, compared to the consensus estimate of $211.29 million. During the same period in the prior year, the company earned $0.25 EPS. Haemonetics Corporation’s revenue for the quarter was up .5% on a year-over-year basis. Equities analysts expect that Haemonetics Corporation will post $1.61 earnings per share for the current year.

Several hedge funds have recently bought and sold shares of the company. US Bancorp DE lifted its holdings in Haemonetics Corporation by 0.6% during the second quarter. US Bancorp DE now owns 22,154 shares of the medical instruments supplier’s stock worth $875,000 after acquiring an additional 141 shares during the period. Tudor Investment Corp ET AL lifted its holdings in Haemonetics Corporation by 0.5% during the second quarter. Tudor Investment Corp ET AL now owns 28,126 shares of the medical instruments supplier’s stock worth $1,111,000 after acquiring an additional 143 shares during the period. Municipal Employees Retirement System of Michigan lifted its holdings in Haemonetics Corporation by 1.3% during the first quarter. Municipal Employees Retirement System of Michigan now owns 11,800 shares of the medical instruments supplier’s stock worth $479,000 after acquiring an additional 150 shares during the period. Louisiana State Employees Retirement System lifted its holdings in Haemonetics Corporation by 0.9% during the second quarter. Louisiana State Employees Retirement System now owns 21,400 shares of the medical instruments supplier’s stock worth $845,000 after acquiring an additional 200 shares during the period. Finally, Rothschild Asset Management Inc. lifted its holdings in Haemonetics Corporation by 0.3% during the second quarter. Rothschild Asset Management Inc. now owns 87,858 shares of the medical instruments supplier’s stock worth $3,470,000 after acquiring an additional 269 shares during the period.

Haemonetics Corporation Company Profile

Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals.

Analyst Recommendations for Haemonetics Corporation (NYSE:HAE)

Receive News & Ratings for Haemonetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply